The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.
medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use liraglutide, nor should individuals who have experienced prior serious hypersensitivity reaction to the drug.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback